文献速递骨质疏松与代谢性骨病骨肿瘤

癌症成人的骨折风险与评估

Fracture risk and assessment in adults with cancer.
PubMed 文献 · Osteoporos Int · 2022-12-13

本文为叙述性综述,总结癌症成人骨质疏松性骨折风险的流行病学负担、骨折风险评估及癌症治疗所致骨丢失的治疗阈值,重点关注乳腺癌、前列腺癌、甲状腺癌、妇科肿瘤、多发性骨髓瘤和造血干细胞移植。癌症及其治疗可从全身和局部影响骨健康,但癌症人群中骨折风险预测工具的验证研究较少,癌症特异性治疗阈值指南有限,仍存在重大知识缺口。

要点

  • 癌症患者面临独特的骨质疏松和骨折风险,需考虑癌症特异性因素与病前骨折风险的叠加效应。
  • 应使用FRAX评分和骨密度检测(如可获得)评估骨折风险,药物治疗应遵循癌症特异性指南或当地一般骨质疏松指南。
  • 激素剥夺治疗(乳腺癌、前列腺癌)和造血干细胞移植等可不良影响骨转换,导致骨质疏松和骨折。

核心结论

  • 癌症可通过多种方式影响骨健康,导致全身和局部骨密度下降,多种癌症治疗对骨健康有不利影响。
  • 癌症人群中骨折风险预测工具的验证研究较少,癌症特异性治疗阈值指南有限,骨折风险及评估仍存在重大知识缺口。
  • 尽管当前知识有限,临床医生必须考虑患者暴露的骨损害因素的叠加效应及其病前骨折风险特征。
  • 药物治疗应遵循癌症特异性指南(如可获得)或当地一般骨质疏松指南,并结合临床判断和患者偏好。

研究设计与样本

  • 叙述性综述,检索PubMed至2022年7月25日,结合癌症、干细胞移植、骨折、骨密度(BMD)、骨小梁评分、FRAX、Garvan列线图或骨折风险计算器、QFracture、预测和风险因素等术语。

主要发现

  • 癌症可以多种方式影响骨健康,导致全身和局部骨密度下降。
  • 激素剥夺治疗用于激素反应性癌症如乳腺癌和前列腺癌,以及血液系统恶性肿瘤的造血干细胞移植,不良影响骨转换,导致骨质疏松和骨折。
  • 妇科癌症的子宫切除术加双侧输卵管卵巢切除术等手术治疗也可对骨健康产生有害影响。
  • 放射治疗已被充分记录可导致局部骨丢失和骨折。
  • 很少有研究验证骨折风险预测工具在癌症人群中的使用。

临床怎么用

  • 临床医生必须考虑癌症患者暴露的骨损害因素的叠加效应及其病前骨折风险特征。
  • 药物治疗应遵循癌症特异性指南(如可获得)或当地一般骨质疏松指南,并结合临床判断和患者偏好。

局限性

  • 很少有研究验证骨折风险预测工具在癌症人群中的使用。
  • 癌症特异性治疗阈值指南有限,骨折风险及评估仍存在重大知识缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals with cancer face unique risk factors for osteoporosis and fractures. Clinicians must consider the additive effects of cancer-specific factors, including treatment-induced bone loss, and premorbid fracture risk, utilizing FRAX score and bone mineral densitometry when available. Pharmacologic therapy should be offered as per cancer-specific guidelines, when available, or local general osteoporosis guidelines informed by clinical judgment and patient preferences. Our objective was to review and summarize the epidemiologic burden of osteoporotic fracture risk and fracture risk assessment in adults with cancer, and recommended treatment thresholds for cancer treatment-induced bone loss, with specific focus on breast, prostate, thyroid, gynecological, multiple myeloma, and hematopoietic stem cell transplant. This narrative review was informed by PubMed searches to July 25, 2022, that combined terms for cancer, stem cell transplantation, fracture, bone mineral density (BMD), trabecular bone score, FRAX, Garvan nomogram or fracture risk calculator, QFracture, prediction, and risk factors. The literature informs that cancer can impact bone health in numerous ways, leading to both systemic and localized decreases in BMD. Many cancer treatments can have detrimental effects on bone health. In particular, hormone deprivation therapies for hormone-responsive cancers such as breast cancer and prostate cancer, and hematopoietic stem cell transplant for hematologic malignancies, adversely affect bone turnover, resulting in osteoporosis and fractures. Surgical treatments such as hysterectomy with bilateral salpingo-oophorectomy for gynecological cancers can also lead to deleterious effects on bone health. Radiation therapy is well documented to cause localized bone loss and fractures. Few studies have validated the use of fracture risk prediction tools in the cancer population. Guidelines on cancer-specific treatment thresholds are limited, and major knowledge gaps still exist in fracture risk and fracture risk assessment in patients with cancer. Despite the limitations of current knowledge on fracture risk assessment and treatment thresholds in patients with cancer, clinicians must consider the additive effects of bone damaging factors to which these patients are exposed and their premorbid fracture risk profile. Pharmacologic treatment should be offered as per cancer-specific guidelines when available, or per local general osteoporosis guidelines, in accordance with clinical judgment and patient preferences.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ye C, Leslie WD. Fracture risk and assessment in adults with cancer. Osteoporos Int. 2022. PMID: 36512057. doi:10.1007/s00198-022-06631-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。